semaglutide mastery course
Unit 11 of 12
comparative efficacy
head-to-head data, mechanism differences, and clinical selection factors
comparative efficacy
semaglutide does not exist in isolation. tirzepatide, the dual GIP/GLP-1 agonist, has shown greater weight loss in head-to-head trials. liraglutide, the first-generation daily GLP-1 agonist, remains widely prescribed with a longer safety track record. this unit compares mechanism differences, clinical trial results across weight loss and glycemic endpoints, cardiovascular outcome data, and the practical factors that drive selection between agents.
use the free framing on this page to orient yourself, then unlock the deeper paid sections, quiz, and exercises for the full lesson.
Interactive Visualization
compare GLP-1 agonists across efficacy, safety, cost, and convenience dimensions.
GLP-1 agonist comparison matrix